Revive Therapeutics Ltd
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious dise… Read more
Revive Therapeutics Ltd (RVVTF) - Net Assets
Latest net assets as of December 2024: $6.39 Million USD
Based on the latest financial reports, Revive Therapeutics Ltd (RVVTF) has net assets worth $6.39 Million USD as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($9.72 Million) and total liabilities ($3.32 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.39 Million |
| % of Total Assets | 65.82% |
| Annual Growth Rate | 19.82% |
| 5-Year Change | -2.65% |
| 10-Year Change | 206.18% |
| Growth Volatility | 220.47 |
Revive Therapeutics Ltd - Net Assets Trend (2014–2024)
This chart illustrates how Revive Therapeutics Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Revive Therapeutics Ltd (2014–2024)
The table below shows the annual net assets of Revive Therapeutics Ltd from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-06-30 | $7.23 Million | -32.11% |
| 2023-06-30 | $10.65 Million | -15.47% |
| 2022-06-30 | $12.60 Million | -56.25% |
| 2021-06-30 | $28.81 Million | +287.76% |
| 2020-06-30 | $7.43 Million | +673.23% |
| 2019-06-30 | $960.78K | +17.01% |
| 2018-06-30 | $821.12K | -49.16% |
| 2017-06-30 | $1.62 Million | +184.05% |
| 2016-06-30 | $568.64K | -75.93% |
| 2015-06-30 | $2.36 Million | +99.25% |
| 2014-06-30 | $1.19 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Revive Therapeutics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6484212882.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $73.42 Million | 1015.19% |
| Total Equity | $7.23 Million | 100.00% |
Revive Therapeutics Ltd Competitors by Market Cap
The table below lists competitors of Revive Therapeutics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kelso Technologies Inc
PINK:KIQSF
|
$5.67 Million |
|
CGX Energy Inc
PINK:CGXEF
|
$5.67 Million |
|
NuGen Medical Devices Inc
OTCQB:NGMDF
|
$5.68 Million |
|
Sammakorn Public Company Limited
BK:SAMCO
|
$5.68 Million |
|
Proodeftiki S.A.
AT:PRD
|
$5.67 Million |
|
Compremum S.A.
WAR:CPR
|
$5.67 Million |
|
Duniec
TA:DUNI
|
$5.67 Million |
|
ABS-CBN Holdings Corporation
PINK:ABSOF
|
$5.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Revive Therapeutics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 10,652,613 to 7,231,974, a change of -3,420,639 (-32.1%).
- Net loss of 5,618,622 reduced equity.
- New share issuances of 2,016,534 increased equity.
- Other factors increased equity by 181,449.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.62 Million | -77.69% |
| Share Issuances | $2.02 Million | +27.88% |
| Other Changes | $181.45K | +2.51% |
| Total Change | $- | -32.11% |
Book Value vs Market Value Analysis
This analysis compares Revive Therapeutics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.80x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-06-30 | $0.00 | $0.01 | x |
| 2016-06-30 | $0.00 | $0.01 | x |
| 2017-06-30 | $0.03 | $0.01 | x |
| 2018-06-30 | $0.01 | $0.01 | x |
| 2019-06-30 | $0.01 | $0.01 | x |
| 2020-06-30 | $0.04 | $0.01 | x |
| 2021-06-30 | $0.09 | $0.01 | x |
| 2022-06-30 | $0.04 | $0.01 | x |
| 2023-06-30 | $0.03 | $0.01 | x |
| 2024-06-30 | $0.02 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Revive Therapeutics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -77.69%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.47x
- Recent ROE (-77.69%) is above the historical average (-140.50%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -99.37% | 0.00% | 0.00x | 1.06x | $-1.30 Million |
| 2015 | -85.99% | 0.00% | 0.00x | 1.13x | $-2.27 Million |
| 2016 | -481.49% | 0.00% | 0.00x | 2.44x | $-2.79 Million |
| 2017 | -100.04% | 0.00% | 0.00x | 1.19x | $-1.78 Million |
| 2018 | -218.10% | 0.00% | 0.00x | 1.36x | $-1.87 Million |
| 2019 | -139.87% | 0.00% | 0.00x | 1.33x | $-1.44 Million |
| 2020 | -72.44% | 0.00% | 0.00x | 1.11x | $-6.12 Million |
| 2021 | -69.84% | 0.00% | 0.00x | 1.03x | $-23.00 Million |
| 2022 | -141.29% | 0.00% | 0.00x | 1.35x | $-19.07 Million |
| 2023 | -59.34% | 0.00% | 0.00x | 1.34x | $-7.39 Million |
| 2024 | -77.69% | 0.00% | 0.00x | 1.47x | $-6.34 Million |
Industry Comparison
This section compares Revive Therapeutics Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Revive Therapeutics Ltd (RVVTF) | $6.39 Million | -99.37% | 0.52x | $5.67 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |